Table of Content

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. Global Dry Age-Related Macular Degeneration Markets: Industry Outlook
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology of Dry AMD
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities

2. Global Dry Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Dry Age-Related Macular Degeneration Market, by Country
2.1.3.1.1 U.S.
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Dry Age-Related Macular Degeneration Market, by Country
2.2.3.1.1 Germany
2.2.3.1.2 U.K.
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.3 Asia Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia Pacific Dry Age-Related Macular Degeneration Market, by Country
2.3.3.1.1 Japan

3. Global Dry Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles
3.1 Key Development and Strategies
3.1.1 Mergers and Acquisitions
3.1.2 Synergistic Activities
3.1.3 Business Expansions and Funding
3.1.4 Product Launches and Approvals
3.1.5 Other Activities
3.2 Company Profiles
3.2.1 AstraZeneca
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Target Customers/End-Users
3.2.1.4 Key Personnel
3.2.1.5 Analyst View
3.2.2 Astellas Pharma
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Target Customers/End-Users
3.2.2.4 Key Personnel
3.2.2.5 Analyst View
3.2.3 Novartis AG.
3.2.3.1 Overview
3.2.3.2 Top Products / Product Portfolio
3.2.3.3 Target Customers/End-Users
3.2.3.4 Key Personnel
3.2.3.5 Analyst View
3.2.4 Apellis Pharmaceuticals
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Target Customers/End-Users
3.2.4.4 Key Personnel
3.2.4.5 Analyst View
3.2.5 Alkeus Pharmaceuticals.
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Target Customers/End-Users
3.2.5.4 Key Personnel
3.2.5.5 Analyst View
3.2.6 Belite Bio.
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Target Customers/End-Users
3.2.6.4 Key Personnel
3.2.6.5 Analyst View
3.2.7 Aviceda Therapeutics
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Target Customers/End-Users
3.2.7.4 Key Personnel
3.2.7.5 Analyst View
3.2.8 Cognition Therapeutics
3.2.8.1 Overview
3.2.8.2 Top Products / Product Portfolio
3.2.8.3 Target Customers/End-Users
3.2.8.4 Key Personnel
3.2.8.5 Analyst View
3.2.9 Annexon Biosciences
3.2.9.1 Overview
3.2.9.2 Top Products / Product Portfolio
3.2.9.3 Target Customers/End-Users
3.2.9.4 Key Personnel
3.2.9.5 Analyst View
3.2.10 Lineage Cell Therapeutics
3.2.10.1 Overview
3.2.10.2 Top Products / Product Portfolio
3.2.10.3 Target Customers/End-Users
3.2.10.4 Key Personnel
3.2.10.5 Analyst View

4. Research Methodology

List of Figures
Figure: Global Dry Age-Related Macular Degeneration Market, Market Overview
Figure: Epidemiology of Dry Age-Related Macular Degeneration
Figure: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023 and 2035
Figure: Global Dry Age-Related Macular Degeneration Market Coverage
Figure: Global Dry Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Dry Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables
Table: Global Dry Age-Related Macular Degeneration Market, Clinical Trial Analysis,
Table: Global Dry Age-Related Macular Degeneration Market Dynamics, Impact Analysis
Table: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035